“Every Bad Decision Possible” – Navidea Shareholders Prepare to Get Squeezed Out

In a recent article published by Columbus Business First, Harter Secrest & Emery Securities & Capital Markets partner and chair Alex R. McClean provided insight on reverse split, a move recently taken by Navidea Biopharmaceuticals, Inc.

Read the full story.

Attorney Advertising. Prior results do not guarantee a similar outcome. This publication is provided as a service to clients and friends of Harter Secrest & Emery LLP. It is intended for general information purposes only and should not be considered as legal advice. The contents are neither an exhaustive discussion nor do they purport to cover all developments in the area. The reader should consult with legal counsel to determine how applicable laws relate to specific situations. ©2024 Harter Secrest & Emery LLP